Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative
N Hammoudi, D Hassid, J Bonnet… - Scandinavian Journal …, 2024 - Taylor & Francis
Background Hypersensitivity reactions (HSR) to the administration of infliximab (IFX) in
Inflammatory Bowel Diseases (IBD) patients are not rare and usually lead to drug …
Inflammatory Bowel Diseases (IBD) patients are not rare and usually lead to drug …
Drug survival of tumor necrosis factor-alpha inhibitors and switched subsequent biologic agents in patients with psoriasis: a retrospective study
M Kishimoto, M Komine, K Kamiya, J Sugai… - Dermatology and …, 2023 - Springer
Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation …
Impact of stress on the immunogenic potential of adalimumab
P Heljo, M Ahmadi, MMH Schack… - Journal of …, 2023 - Elsevier
Monoclonal antibodies against tumor necrosis factor-alpha (TNFα) are widely used for
treatment of inflammatory diseases. However, despite the inhibitory effect this class of drugs …
treatment of inflammatory diseases. However, despite the inhibitory effect this class of drugs …
Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review
T Liao, M Li, T Yuan, Q Hong, Y Zeng, D Yu… - Frontiers in …, 2022 - frontiersin.org
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint
inflammation. In recent decades, biological agents such as anti-tumor necrosis factor-α (TNF …
inflammation. In recent decades, biological agents such as anti-tumor necrosis factor-α (TNF …
Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
Z Yu, L Gao, Y Zang, L Cheng… - Immunity, Inflammation …, 2024 - Wiley Online Library
Introduction Adalimumab (ADA) and etanercept (ETN) are the most commonly applied
biologics for rheumatoid arthritis (RA) management in China; however, the evidence …
biologics for rheumatoid arthritis (RA) management in China; however, the evidence …
Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation
C Karsten, K Grannas, O Bergman, R Movérare… - The AAPS Journal, 2024 - Springer
Monitoring anti-drug antibodies (ADAs) to infliximab and adalimumab is critical to treatment
management in various autoimmune disorders. The growing need for proactive therapeutic …
management in various autoimmune disorders. The growing need for proactive therapeutic …
Case Report: Patient with deficiency of ADA2 presenting leukocytoclastic vasculitis and pericarditis during infliximab treatment
D Simão Raimundo, AI Cordeiro… - Frontiers in …, 2023 - frontiersin.org
Deficiency of adenosine deaminase 2 (DADA2), first reported in 2014, is a disease with
great phenotypic variability, which has been increasingly reported. Therapeutic response …
great phenotypic variability, which has been increasingly reported. Therapeutic response …
Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing …
Š Tichý, L Nekvindová, J Baranová… - Scandinavian Journal …, 2024 - Taylor & Francis
Objectives To compare the drug survival of etanercept to monoclonal tumour necrosis factor-
α inhibitors in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Methods …
α inhibitors in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Methods …
[HTML][HTML] 结肠炎癌转化调控机制和化学干预的研究进展
刘怡彤, 孙洋 - 药学学报, 2022 - html.rhhz.net
结直肠癌是消化道常见恶性肿瘤, 炎症性肠病发展为结直肠癌的风险显著增加. 免疫信号通路NF-
κB, IL-6/STAT3, COX-2/PGE2, IL-23/Th17, TLRs 等已被证实能够促进结肠炎向结直肠癌转化 …
κB, IL-6/STAT3, COX-2/PGE2, IL-23/Th17, TLRs 等已被证实能够促进结肠炎向结直肠癌转化 …
[HTML][HTML] Trajectories of systemic agent use and associated depression-and anxiety-related health care costs among patients with psoriasis
R Milan, J LeLorier, EA Latimer, MJ Brouillette… - JAAD international, 2022 - Elsevier
Background Systemic treatment patterns and related mental health disorders and economic
burden among patients with psoriasis are largely unknown. Objective To assess systemic …
burden among patients with psoriasis are largely unknown. Objective To assess systemic …